Fernando Rivera — ASN Events

Fernando Rivera — ASN Events

, ,

Presentations this author is a contributor to:

Analysis of KRAS/NRAS mutations in PEAK: A randomised phase II study of FOLFOX6 plus panitumumab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) (#19)

Lee Schwartzberg